Introduction

E. Strong (ed.). Gastric cancer. Principles and practice. Springer (2015)


Gastric cancer is diagnosed in over 1 million individuals each year worldwide and the second most common cause of cancer-related death [1]. For localized disease, surgical resection is the cornerstone of curative treatment. Unfortunately, even after curative surgery and peri-operative chemotherapy, many patients will recur and develop metastatic disease. Standard chemotherapy for advanced gastric cancer results in response rates in 20–40% and median survival of only 8–10 months [2]. There is clearly a need for more specific targeted therapies to improve the current status of systemic treatment beyond conventional chemotherapy. Human epidermal growth factor receptor 2 (HER2) is the first validated treatment target in esophagogastric cancer based on the results of trastuzumab in combination with chemotherapy for treatment of HER2positive advanced gastric or gastroesophageal junction (GEJ) cancer in the trastuzumab for gastric cancer (ToGA) trial [3].

[contact-form-7 id=»5168″ title=»Контактная форма 1″]

0

Добавить комментарий

Войти с помощью: 

Ваш e-mail не будет опубликован. Обязательные поля помечены *